Coya Therapeutics, Inc.
$4.99
▼
-1.72%
2026-04-21 06:11:00
www.coyatherapeutics.com
NCM: COYA
Explore Coya Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$112.13 M
Current Price
$4.99
52W High / Low
$7.75 / $3.71
Stock P/E
—
Book Value
$2.06
Dividend Yield
—
ROCE
-51.17%
ROE
-51.39%
Face Value
—
EPS
$-1.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
0.52
Debt / Equity
—
Current Ratio
8.51
Quick Ratio
8.5
Forward P/E
-3.61
Price / Sales
12.31
Enterprise Value
$50.99 M
EV / EBITDA
-2.52
EV / Revenue
6.42
Rating
Strong Buy
Target Price
$15.64
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 2. | Foghorn Therapeutics Inc. | $5.51 | — | $310.52 M | — | -59.34% | 96.45% | $6.95 / $3.27 | $-1.92 |
| 3. | Galectin Therapeutics Inc. | $2.29 | — | $156.67 M | — | -174.62% | 26.9% | $7.13 / $1.21 | $-1.97 |
| 4. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
| 5. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 6. | Neurogene Inc. | $27.74 | — | $432.03 M | — | -37.96% | -31.41% | $37.27 / $10.46 | $17.1 |
| 7. | Liminatus Pharma, Inc. | $0.22 | — | $9.83 M | — | 30.51% | — | $33.66 / $0.16 | $-0.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.96 M | 3.56 M | 0.16 M | 0.26 M | 0 M | — |
| Operating Profit | -6.03 M | -2.43 M | -6.41 M | -7.68 M | -4.08 M | — |
| Net Profit | -5.71 M | -2.12 M | -6.09 M | -7.31 M | -2.92 M | — |
| EPS in Rs | -0.24 | -0.09 | -0.26 | -0.31 | -0.12 | -0.26 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.95 M | 3.55 M | 6 M | 0 M |
| Operating Profit | -22.56 M | -17.25 M | -7.9 M | -9.81 M |
| Net Profit | -21.23 M | -14.88 M | -7.99 M | -12.24 M |
| EPS in Rs | -0.9 | -0.63 | -0.34 | -0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 49.95 M | 44.35 M | 41.26 M | 8.4 M |
| Total Liabilities | 6.92 M | 4.77 M | 5.63 M | 16.79 M |
| Equity | 43.03 M | 39.58 M | 35.64 M | -8.39 M |
| Current Assets | 49.94 M | 44.31 M | 41.2 M | 7.18 M |
| Current Liabilities | 5.87 M | 3.82 M | 5.05 M | 3.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.74 M | -10.29 M | -11.19 M | -7.24 M |
| Investing CF | -1.16 M | -0.03 M | -0.54 M | -0.53 M |
| Financing CF | 20.39 M | 16.03 M | 38.43 M | 9.36 M |
| Free CF | -10.74 M | -10.29 M | -11.19 M | -7.24 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -40.79% | — | — | — |
| Earnings Growth % | -86.29% | 34.77% | — | — |
| Profit Margin % | -418.7% | -133.08% | — | — |
| Operating Margin % | -485.35% | -131.67% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -484.58% | -131.22% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.